ライフサイエンスコーパス: systemic sclerosis

1 ethylome in primary T cells of patients with systemic sclerosis.

2 cells and skin transcriptome changes, as in systemic sclerosis.

3 een in patients with the autoimmune disease, systemic sclerosis.

4 n 156 patients with severe diffuse cutaneous systemic sclerosis.

5 link between epidermal c-Rel expression and systemic sclerosis.

6 is and of other fibrotic disorders including systemic sclerosis.

7 in progressive vasculopathy in patients with systemic sclerosis.

8 atment of pulmonary arterial hypertension in systemic sclerosis.

9 pecimens of skin and lung from patients with systemic sclerosis.

10 lung injury, including that associated with systemic sclerosis.

11 of morbidity and mortality in patients with systemic sclerosis.

12 s as potential therapeutic interventions for systemic sclerosis.

13 the vascular manifestations associated with systemic sclerosis.

14 leading cause of mortality in patients with systemic sclerosis.

15 general population and >90% of patients with systemic sclerosis.

16 ease and severe skin disease associated with systemic sclerosis.

17 ase-modifying therapies for the treatment of systemic sclerosis.

18 released in a higher amount in patients with systemic sclerosis.

19 the sera of patients with diffuse cutaneous systemic sclerosis.

20 s a concern in an autoimmune disease such as systemic sclerosis.

21 therapies promise to have a major impact in systemic sclerosis.

22 on on platelet contributions, in general, to systemic sclerosis.

23 aggregation in different forms and stages of systemic sclerosis.

24 atibility complex haplotypes associated with systemic sclerosis.

25 ciencies of these surrogates in the study of systemic sclerosis.

26 d with immune-mediated conditions, including systemic sclerosis.

27 atins may be effective therapeutic agents in systemic sclerosis.

28 sociation (P = 8.5 x 10(-22); OR = 4.3) with systemic sclerosis.

29 he faSScinate phase 2 trial in patients with systemic sclerosis.

30 l class of genes involved in pathogenesis of systemic sclerosis.

31 , including systemic lupus erythematosus and systemic sclerosis.

32 ures, whose pathogenesis may be similar with systemic sclerosis.

33 tions in five large cohorts of patients with systemic sclerosis.

34 CXCL4 predicted the risk and progression of systemic sclerosis.

35 rticipants, the nailfolds in 2 patients with systemic sclerosis, 1 patient with dermatomyositis, and

36 ) has been implicated in driving fibrosis in systemic sclerosis, a mechanism-derived gene expression

37 osus affects from 161,000 to 322,000 adults, systemic sclerosis affects 49,000 adults, and primary Sj

38 Endothelin-1 promotes vasculopathy in systemic sclerosis after macitentan, an endothelin-1 blo

39 Systemic sclerosis, also called scleroderma, is an immun

40 st potential efficacy of imatinib in diffuse systemic sclerosis, although adverse events are common.

41 ical and histopathological similarities with systemic sclerosis, an autoimmune disease whose risk is

42 Participants were patients with systemic sclerosis and active digital ulcers at baseline

43 Among patients with systemic sclerosis and active ischemic digital ulcers, t

44 g pathways and mediators that are altered in systemic sclerosis and contribute to tissue damage allow

45 entially regulated between diffuse cutaneous systemic sclerosis and controls and correlated with modi

46 vels of CXCL4 were elevated in patients with systemic sclerosis and correlated with the presence and

47 microcirculation plays an important role in systemic sclerosis and dermatomyositis.

48 Here, we review the clinical features of systemic sclerosis and describe the best practice approa

49 ession profiling studies of animal models of systemic sclerosis and explanted fibroblasts have helped

50 proteome of patients with diffuse cutaneous systemic sclerosis and identified differentially express

51 ling and participates in the pathogenesis of systemic sclerosis and idiopathic pulmonary fibrosis.

52 s aberrantly expressed in lesional tissue in systemic sclerosis and in a murine model of scleroderma.

53 s with diffuse systemic sclerosis or limited systemic sclerosis and interstitial lung disease who wer

54 the prototypic fibrotic autoimmune condition systemic sclerosis and is known to induce collagen I exp

55 nt an attractive target for the treatment of systemic sclerosis and other fibrosing disorders.

56 pathway may represent a novel treatment for systemic sclerosis and other fibrotic diseases.

57 allmark of many fibrotic diseases, including systemic sclerosis and pulmonary, liver, and kidney fibr

58 characterized autoimmune diseases, including systemic sclerosis and Sjogren syndrome.

59 sma levels of CXCL4 protein with features of systemic sclerosis and studied the direct effects of CXC

60 eir receptor has been noted in patients with systemic sclerosis and systemic lupus erythematosus with

61 tic studies on stem cell transplantation for systemic sclerosis and their implications for clinical p

62 complications are important in scleroderma (systemic sclerosis) and include scleroderma renal crisis

63 c lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and anti-neutrophil cytoplasmic anti

64 s in these mediators have been identified in systemic sclerosis, and may account for the characterist

65 Genetic components associated with systemic sclerosis are also associated with sclerotic GV

66 Digital ulcers in patients with systemic sclerosis are associated with pain and poor qua

67 chronically elevated endogenous IFNs such as systemic sclerosis are strongly associated with PAH.

68 vels were elevated in serum of patients with systemic sclerosis associated PAH.

69 s that can be learnt from clinical trials of systemic sclerosis-associated ILD and idiopathic pulmona

70 Patients with systemic sclerosis-associated interstitial lung disease

71 age (BAL) cellular profiles in patients with systemic sclerosis-associated interstitial lung disease

72 Histologic assessment of patients with systemic sclerosis-associated PAH and the hypoxia/SU5416

73 uded vessels in patients with idiopathic and systemic sclerosis-associated PAH.

74 Systemic sclerosis-associated pulmonary artery hypertens

75 or autoimmune (polymyositis/dermatomyositis, systemic sclerosis, autoimmune hemolytic anemia, pernici

76 secreted by plasmacytoid dendritic cells in systemic sclerosis, both in circulation and in skin.

77 ransplantation (HSCT) benefits patients with systemic sclerosis but has been associated with signific

78 ve treatment option for patients with severe systemic sclerosis, but is associated with toxicity and

79 In the 2 patients with systemic sclerosis, D-OCT depicted megacapillaries, as w

80 mortality in patients with diffuse cutaneous systemic sclerosis (dcSSc).

81 by DNA microarray from 13 diffuse cutaneous systemic sclerosis (dSSc) patients enrolled in an open-l

82 miR-135b was measured in systemic sclerosis fibroblasts isolated from patients an

83 or the characteristic activated phenotype of systemic sclerosis fibroblasts.

84 ype I collagen gene expression in normal and systemic sclerosis fibroblasts.

85 oposed that play a role in susceptibility to systemic sclerosis; firstly the maintenance of immune to

86 skin and pulmonary function in patients with systemic sclerosis for up to 2 years and is preferable t

87 date major histocompatibility complex-linked systemic sclerosis genetics, we performed genotyping of

88 Improved understanding of systemic sclerosis has allowed better management of the

89 ly a small proportion of the heritability of systemic sclerosis has been explained.

90 as a potential strategy for the treatment of systemic sclerosis has been gaining more widespread inte

91 cent studies of gene expression profiling in systemic sclerosis have demonstrated its value in diagno

92 opoietic stem-cell transplantation (HSCT) in systemic sclerosis have shown improvements in lung funct

93 In light of the complex pathogenesis of systemic sclerosis, however, only carefully designed cli

94 specially juvenile dermatomyositis (JDM) and systemic sclerosis; however, little is known about the p

95 Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased t

96 een concluded: the nonmyeloablative American Systemic Sclerosis Immune Suppression versus Transplant,

97 allele for systemic lupus erythematosus and systemic sclerosis in non-Hispanic white or Chinese subj

98 ransplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small phase 2 trials.

99 The spectrum of renal complications in systemic sclerosis includes scleroderma renal crisis (SR

100 Systemic sclerosis is a complex disease characterized by

101 Systemic sclerosis is a complex disease with widespread

102 Systemic sclerosis is a major risk factor for the develo

103 Systemic sclerosis is a rare disabling autoimmune diseas

104 Systemic sclerosis is a rare, often lethal, disorder of

105 Systemic sclerosis is a systemic autoimmune and connecti

106 Systemic sclerosis is an autoimmune connective tissue di

107 Systemic sclerosis is an autoimmune disease characterize

108 Systemic sclerosis is an autoimmune disease characterize

109 Systemic sclerosis is an orphan, systemic autoimmune dis

110 Systemic sclerosis is commonly complicated by pulmonary

111 ibutions of platelets to the pathogenesis of systemic sclerosis is likely substantial and may not be

112 of non-lethal complications associated with systemic sclerosis is substantial and is likely to becom

113 Although systemic sclerosis is uncommon, it has a high morbidity

114 n several inflammatory skin diseases, yet in systemic sclerosis, it can occur in all regions of the d

115 roblast in diverse fibrotic lesions, such as systemic sclerosis; kidney, liver, and lung fibrosis; an

116 vascular manifestations of limited cutaneous systemic sclerosis (lcSSc) and in the prevention of the

117 , a common complication of limited cutaneous systemic sclerosis (lcSSc), is associated with alteratio

118 studies with rituximab in diffuse cutaneous systemic sclerosis lend support that B cells may be impo

119 diseases, including the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular dise

120 Caveolin-1 was reduced in affected systemic sclerosis lungs and skin and in idiopathic pulm

121 Women with systemic sclerosis manifest an enhanced rate of X monoso

122 derstanding of the disease in the context of systemic sclerosis may lead to novel diagnostic and ther

123 were aged younger than 60 years with diffuse systemic sclerosis, modified Rodnan skin scores (mRSS) o

124 temic lupus erythematosus (SLE) (n = 7,241), systemic sclerosis (n = 5,642), or other systemic autoim

125 Pulmonary arterial hypertension complicating systemic sclerosis occurs commonly and portends a poor p

126 We enrolled adults with progressive systemic sclerosis of 5 or fewer years' duration from fi

127 We assessed patients with diffuse systemic sclerosis or limited systemic sclerosis and int

128 kin fibroblasts from individuals with either systemic sclerosis or recessive dystrophic epidermolysis

129 idosis or collagen vascular diseases such as systemic sclerosis or rheumatoid arthritis; however, eac

130 Systemic sclerosis or scleroderma (SSc) is a complex aut

131 novo emergence of myofibroblasts such as in systemic sclerosis or scleroderma.

132 d coding and non-coding genes in relation to systemic sclerosis pathogenesis with a specific focus on

133 nd thereby improve the state of knowledge of systemic sclerosis pathogenesis.

134 I IFN-associated genes might be critical in systemic sclerosis pathogenesis.

135 assays of CD4(+) and CD8(+) T cells from 24 systemic sclerosis patients and 24 matched controls were

136 l randomized, controlled phase 2 trial in 19 systemic sclerosis patients and a large randomized phase

137 mer group, AKA were present in 4 of 20 (20%) systemic sclerosis patients and in 3 of 12 (25%) ankylos

138 Skin biopsy-derived RNAs from 14 early systemic sclerosis patients and six healthy individuals

139 oding RNAs are deregulated in skin tissue of systemic sclerosis patients suggesting a novel class of

140 ospective analyses of independent cohorts of systemic sclerosis patients treated with autologous stem

141 Stem cell transplantation of systemic sclerosis patients with lung involvement result

142 healthy human skin disappear in the skin of systemic sclerosis patients, and CD34(-), podoplanin(+),

143 is dysfunctional at the epigenetic level in systemic sclerosis patients, indicating that hypomethyla

144 o provide valuable prognostic information in systemic sclerosis patients.

145 ) were significantly elevated in the sera of systemic sclerosis patients.

146 In a cohort of systemic sclerosis patients/controls, SFVT analysis show

147 This activation phenotype of systemic sclerosis platelets may be secondary to autoimm

148 ion of a type I collagen receptor would make systemic sclerosis platelets more susceptible to binding

149 A recent finding is that systemic sclerosis platelets overexpress a specific noni

150 In this study, we replicated key features of systemic sclerosis-related PAH in a mouse model.

151 with pulmonary hypertension (166 SScPAH, 49 systemic sclerosis-related pulmonary hypertension with i

152 We tested whether SScPAH or systemic sclerosis-related pulmonary hypertension with i

153 y patient with polymyositis/dermatomyositis, systemic sclerosis, rheumatoid arthritis, or Sjogren's s

154 Cardiac involvement in systemic sclerosis (scleroderma [SSc]) adversely affects

155 The lung in systemic sclerosis (scleroderma) is susceptible to fibro

156 Systemic sclerosis (scleroderma, SSc) is a devastating f

157 Gastrointestinal tract (GIT) involvement in systemic sclerosis (scleroderma, SSc) is the most common

158 nderstanding of fibrosis and vasculopathy in systemic sclerosis, scleroderma (SSc) largely mediated t

159 Skin biopsies from patients with systemic sclerosis show robust changes in gene profile t

160 rials to assess changes in diffuse cutaneous systemic sclerosis skin disease over time.

161 c-Rel subunits within lesional psoriatic and systemic sclerosis skin revealed abnormal epidermal expr

162 ic autoimmune disease, and from RA, SLE, and systemic sclerosis, specifically.

163 te disease phenotypes in fibrillin-1 mutated systemic sclerosis (SS) and dextran-sulfate-sodium-induc

164 n extra-cutaneous organ system involved with systemic sclerosis (SSc) affecting approximately 90% of

165 Systemic sclerosis (SSc) affects both microvascular stru

166 To assess health values in subjects with systemic sclerosis (SSc) and determine variability expla

167 occurs in approximately 90% of patients with systemic sclerosis (SSc) and has a major impact on healt

168 owth factor (CTGF; CCN2) is overexpressed in systemic sclerosis (SSc) and has been hypothesized to be

169 data for elucidating the molecular basis of systemic sclerosis (SSc) and its various clinical manife

170 ltured dermal fibroblasts from patients with systemic sclerosis (SSc) and nephrogenic systemic fibros

171 the importance of interleukin-13 (IL-13) in systemic sclerosis (SSc) and other fibrotic diseases, it

172 dy is to investigate the association between systemic sclerosis (SSc) and periodontitis.

173 aberrant Wnt signaling has been linked with systemic sclerosis (SSc) and pulmonary fibrosis, we soug

174 ers (CTDs), including Marfan syndrome (MFS), systemic sclerosis (SSc) and Tight-skin (Tsk) mice.

175 e, incidence, survival, and risk factors for systemic sclerosis (SSc) and to compare these data to pr

176 tivation of the Smad1 pathway in fibrosis in systemic sclerosis (SSc) and to determine whether this p

177 increased in a large cohort of patients with systemic sclerosis (SSc) and whether OPN contributes to

178 Improved outcome measures in systemic sclerosis (SSc) are critical to finding active

179 for maintaining persistent organ fibrosis in systemic sclerosis (SSc) are not known but emerging evid

180 at Wnts might contribute to skin fibrosis in systemic sclerosis (SSc) by affecting the differentiatio

181 In this study, 1,833 systemic sclerosis (SSc) cases and 3,466 controls were g

182 , observational study of a multiethnic early systemic sclerosis (SSc) cohort.

183 Heterogeneity in systemic sclerosis (SSc) confounds clinical trials.

184 blood cells (PBMCs) from some patients with systemic sclerosis (SSc) express an interferon-alpha (IF

185 and to determine the sensitivity of cultured systemic sclerosis (SSc) fibroblasts to Akt inhibition.

186 study was undertaken to examine responses of systemic sclerosis (SSc) fibroblasts to sphingosine 1-ph

187 btained from a small number of patients with systemic sclerosis (SSc) has been reported as confirmati

188 ells responsible for the intimal fibrosis in systemic sclerosis (SSc) has not been fully identified.

189 BACKGROUND & AIMS: Patients with systemic sclerosis (SSc) have impairments in gastrointes

190 Systemic sclerosis (SSc) is a chronic idiopathic disease

191 Systemic sclerosis (SSc) is a complex human disorder cha

192 Systemic sclerosis (SSc) is a connective tissue disorder

193 Systemic sclerosis (SSc) is a disorder of systemic and d

194 Systemic sclerosis (SSc) is a generalized disorder of un

195 n present clinically, cardiac involvement in systemic sclerosis (SSc) is a major risk factor for deat

196 Systemic sclerosis (SSc) is a multi-organ fibrotic disea

197 Systemic sclerosis (SSc) is a multisystem inflammatory a

198 Systemic sclerosis (SSc) is a polygenic, autoimmune diso

199 Systemic sclerosis (SSc) is a rare systemic autoimmune d

200 Systemic sclerosis (SSc) is a spreading fibrotic disease

201 Skin fibrosis in systemic sclerosis (SSc) is accompanied by attrition of

202 Systemic sclerosis (SSc) is an autoimmune disease charac

203 Systemic sclerosis (SSc) is an autoimmune disease charac

204 Systemic sclerosis (SSc) is an autoimmune disease charac

205 Systemic sclerosis (SSc) is an autoimmune disease marked

206 Systemic sclerosis (SSc) is an autoimmune disorder chara

207 Systemic sclerosis (SSc) is an autoimmune disorder that

208 Systemic sclerosis (SSc) is associated with vasculopathy

209 Systemic sclerosis (SSc) is characterized by calcificati

210 Systemic sclerosis (SSc) is characterized by chronic inf

211 Systemic sclerosis (SSc) is manifested by fibrosis, vasc

212 Epidemiology studies suggest that systemic sclerosis (SSc) is more common, occurs at a you

213 Dermal fibroblasts were isolated from systemic sclerosis (SSc) patients and healthy control su

214 ulmonary vasculature of <2 mm in diameter in Systemic Sclerosis (SSc) patients with (n = 17) and with

215 ight stimulate both of these key features of systemic sclerosis (SSc) RECENT FINDINGS: Nucleic acid c

216 The role of tumor necrosis factor (TNF) in systemic sclerosis (SSc) remains controversial.

217 Systemic sclerosis (SSc) remains one of the last severe

218 amics and exercise capacity in patients with systemic sclerosis (SSc) spectrum-associated ePH treated

219 A unique feature of systemic sclerosis (SSc) that distinguishes it from othe

220 mononuclear cells (PBMCs) from patients with systemic sclerosis (SSc) to better understand the dysreg

221 t the baseline visit (V0), 203 patients with systemic sclerosis (SSc) were examined (104 whites, 39 A

222 Systemic sclerosis (SSc), a collagen vascular disease ch

223 In systemic sclerosis (SSc), a common and aetiologically my

224 T lymphocytes play an important role in systemic sclerosis (SSc), a connective tissue disease ch

225 CD8(+)CD28(-) T cells in the pathogenesis of systemic sclerosis (SSc), a connective tissue disorder c

226 in the peripheral blood of individuals with systemic sclerosis (SSc), a disease characterized by fib

227 Systemic sclerosis (SSc), also known as scleroderma, is

228 ggested a role for pathogens as a trigger of systemic sclerosis (SSc), although neither a pathogen no

229 nchoalveolar lavage fluid from patients with systemic sclerosis (SSc), and in a CCL18 overexpression

230 need for effective antifibrotic therapies in systemic sclerosis (SSc), and in parallel a rapid develo

231 vement with dermal fibrosis is a hallmark of systemic sclerosis (SSc), and keratinocytes may be criti

232 ity in vitro and has long been implicated in systemic sclerosis (SSc), as expression of TGF-beta-regu

233 Fibrosis, the hallmark of systemic sclerosis (SSc), is characterized by persistent

234 Systemic sclerosis (SSc), or scleroderma, is a heterogen

235 n (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be isolated (pulm

236 ating tight skin (Tsk(-/+)) mice, a model of systemic sclerosis (SSc), with 4F decreases inflammation

237 uss recent advances in serologic testing for systemic sclerosis (SSc)-associated antibodies with resp

238 s now been shown to reduce the number of new systemic sclerosis (SSc)-related digital ulcers in two m

239 th factor (PDGF) may play a critical role in systemic sclerosis (SSc)-related interstitial lung disea

240 Systemic sclerosis (SSc)-related pulmonary fibrosis, for

241 o be observed in fibrotic disorders, such as systemic sclerosis (SSc).

242 critical early event in the pathogenesis of systemic sclerosis (SSc).

243 have been implicated in the pathogenesis of systemic sclerosis (SSc).

244 ung disease is the leading cause of death in systemic sclerosis (SSc).

245 or contributor to morbidity and mortality in systemic sclerosis (SSc).

246 Wnt/beta-catenin signaling in the context of systemic sclerosis (SSc).

247 proteins underlies the fibrotic phenotype of systemic sclerosis (SSc).

248 leading cause of mortality in patients with systemic sclerosis (SSc).

249 an important cause of death in patients with systemic sclerosis (SSc).

250 ly has a crucial role in the pathogenesis of systemic sclerosis (SSc).

251 the leading causes of death in patients with systemic sclerosis (SSc).

252 is implicated as a participatory pathway in systemic sclerosis (SSc).

253 gene expression in the skin of patients with systemic sclerosis (SSc).

254 re required for patients with poor-prognosis systemic sclerosis (SSc).

255 kingly similar to that seen in patients with systemic sclerosis (SSc).

256 st activation in fibrotic diseases including systemic sclerosis (SSc).

257 FNs are implicated in the pathophysiology of systemic sclerosis (SSc).

258 data and interstitial lung disease (ILD) - a systemic sclerosis (SSc, or scleroderma) clinical phenot

259 exist in the susceptibility and severity of systemic sclerosis (SSc, scleroderma) and are responsibl

260 ry fibrosis is an important manifestation in systemic sclerosis (SSc, scleroderma) where it portends

261 PAH associated with systemic sclerosis (SSc-PAH) has a substantially worse p

262 arterial hypertension (PAH) associated with systemic sclerosis (SSc-PAH).

263 African American and Caucasian patients with systemic sclerosis (SSc; scleroderma) and in healthy ind

264 and its receptor, PDGFR, promote fibrosis in systemic sclerosis (SSc; scleroderma) dermal fibroblasts

265 cted first-degree relatives within multicase systemic sclerosis (SSc; scleroderma) families are conco

266 The underlying pathogenesis of systemic sclerosis (SSc; scleroderma) involves a complex

267 Systemic sclerosis (SSc; scleroderma) is a systemic conn

268 Systemic sclerosis (SSc; scleroderma) is characterized b

269 atures and natural history of the disease in systemic sclerosis (SSc; scleroderma) patients with anti

270 leading cause of morbidity and mortality in systemic sclerosis (SSc; scleroderma), and interstitial

271 biopsy specimens obtained from patients with systemic sclerosis (SSc; scleroderma), and that specific

272 enda for research on psychosocial aspects of systemic sclerosis (SSc; scleroderma).

273 fibrosis, the most characteristic feature of systemic sclerosis (SSc; scleroderma).

274 Scleroderma (systemic sclerosis [SSc]) is a complex connective tissue

275 tissue growth factor (CTGF) in scleroderma (systemic sclerosis [SSc]) lung fibroblasts.

276 Scleroderma (systemic sclerosis [SSc]), is characterized by progressi

277 any chronic diseases, including scleroderma (systemic sclerosis [SSc]).

278 ducing functional disability in scleroderma (systemic sclerosis; SSc).

279 S scores comparable with scores reported for systemic sclerosis, systemic lupus erythematosus, and mu

280 ncluding systemic lupus erythematosus (SLE), systemic sclerosis, Takayasu arteritis, Wegener granulom

281 y of proteins not previously associated with systemic sclerosis that provide insight into pathogenesi

282 sorders, such as scleroderma and progressive systemic sclerosis, the direct consequences of IL-33 rel

283 In systemic sclerosis, these repair processes appear to run

284 have been implicated in the pathogenesis of systemic sclerosis through mechanisms beyond the previou

285 adequately represented in gene profiling of systemic sclerosis tissue due to the small amounts of RN

286 ular localization of the protein in affected systemic sclerosis tissues and demonstrated its expressi

287 lines for cardiac screening of patients with systemic sclerosis to assess treatment-related risk from

288 that have a well-documented association with systemic sclerosis to determine whether these SNPs are a

289 ess in understanding genetic associations of systemic sclerosis to explain the observed heritability.

290 ion data from skin biopsies of patients with systemic sclerosis treated with five therapies: mycophen

291 mean (+/-SD) level of CXCL4 in patients with systemic sclerosis was 25,624+/-2652 pg per milliliter,

292 ed and unequivocally effective currently for systemic sclerosis, we have come a long way in the past

293 six healthy volunteers and six patients with systemic sclerosis were imaged at 1.5-T nonenhanced FSD

294 9, 156 patients with early diffuse cutaneous systemic sclerosis were recruited and followed up until

295 -three patients with early diffuse cutaneous systemic sclerosis were studied at 11 international cent

296 thritis [RA], 12 psoriatic arthritis, and 12 systemic sclerosis) were recruited together with 12 heal

297 o cohorts of patients with diffuse cutaneous systemic sclerosis, were identified as differentially re

298 appear to operate in Sjogren's syndrome and systemic sclerosis whereas only the IRF5-TNPO3 gene-span

299 cterization of the phenotype of platelets in systemic sclerosis which will be reviewed.

300 from healthy persons and from patients with systemic sclerosis who had distinct clinical phenotypes.